Azapeptides and their therapeutic potential

Future Medicinal Chemistry

Volumn 3, Issue 9, 2011, Pages 1139-1164

  Proulx, Caroline ^a   Sabatino, David ^a,b   Hopewell, Robert ^a   Spiegel, Jochen ^a,c   García Ramos, Yésica ^a   Lubell, William D ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b SETON HALL UNIVERSITY   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZAPEPTIDE; BETA LACTAM; CARBAMIC ACID; CARBON; COPPER; CYSTEINE PROTEINASE INHIBITOR; ELECTROPHILE; GLUTAMIC ACID; HYDANTOIN; HYDRAZIDE; HYDRAZINE; ISOCYANATE; LIGAND; NITROGEN; PEPTIDE DERIVATIVE; PHOSGENE; PROLINE; PROTEINASE INHIBITOR; PYRAZOLINE DERIVATIVE; SEMICARBAZONE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; UREA;

AB INITIO CALCULATION; ACYLATION; ALKYLATION; ALPHA CHAIN; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO ACID TRANSPORT; AMINO TERMINAL SEQUENCE; ARYLATION; BINDING SITE; CATALYSIS; CIRCULAR DICHROISM; CROSS COUPLING REACTION; CYCLIZATION; DENSITY FUNCTIONAL THEORY; DEPROTECTION REACTION; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; GEOMETRY; HYBRID; HYDROGEN BOND; HYDROGENATION; HYDROGENOLYSIS; INFRARED SPECTROSCOPY; MITSUNOBU REACTION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEOPHILICITY; PEPTIDE SYNTHESIS; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN MODIFICATION; REACTION TIME; REDUCTION; REVIEW; SAPONIFICATION; SUBSTITUTION REACTION; X RAY CRYSTALLOGRAPHY;

AZA COMPOUNDS; ENZYME INHIBITORS; HUMANS; MOLECULAR CONFORMATION; PEPTIDES; SEMICARBAZIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79961059524     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.74     Document Type: Review

References (109)

1. Gray CJ, Quibell M, Baggett N, Hammerle T. Incorporation of azaglutamine residues into peptides synthesised by the ultra-high load solid (gel)-phase technique. Int. J. Peptide Protein Res. 40(5), 351-362 (1992).
2. Liley M, Johnson T. Solid phase synthesis of azapeptides utilising reversible amide bond protection to prevent hydantoin formation. Tetrahedron Lett. 41(20), 3983-3985 (2000). (Pubitemid 30340108)
3. Ahn IA, Woong Kim S, Ro S. Solid phase synthesis of azapeptides using an automatic synthesizer. Mol. Divers. 4(1), 23-24(1998). (Pubitemid 128513922)
4. Verhelst SHL, Witte MD, Arastu-Kapur S, Fonovic M, Bogyo M. Novel aza peptide inhibitors and active-site probes of papain-family cysteine proteases. Chem. Bio. Chem. 7(6), 943-950 (2006). (Pubitemid 43938617)
5. Melendez RE, Lubell WD. Aza-amino acid scan for rapid identification of secondary structure based on the application of N-Boc-aza1-dipeptides in peptide synthesis. J. Am. Chem. Soc. 126(21), 6759-6764 (2004). (Pubitemid 38697375)
6. Nowick JS, Powell NA, Nguyen TM, Noronha G. An improved method for the synthesis of enantiomerically pure amino acid ester isocyanates. J. Org. Chem. 57(26), 7364-7366 (1992).
7. André F, Marraud M, Tsouloufis T, Tzartos SJ, Boussard G. Triphosgene: an efficient carbonylating agent for liquid and solid-phase aza-peptide synthesis. Application to the synthesis of two aza-analogues of the AChR MIR decapeptide. J. Pept. Sci. 3(6), 429-441 (1997). (Pubitemid 127541466)
8. Frochot C, Vanderesse R, Driou A, Linden G, Marraud M, Thong Cung M. A solid-phase synthesis of three aza-, iminoaza- and reduced aza-peptides from the same precursor. Lett. Pept. Sci. 4(4), 219-225 (1997). (Pubitemid 127505450)
9. Bourguet CB, Proulx C, Klocek S, Sabatino D, Lubell WD. Solution-phase submonomer diversification of aza-dipeptide building blocks and their application in aza-peptide and aza-DKP synthesis. J. Pept. Sci. 16(6), 284-296 (2010).
10. Sabatino D, Proulx C, Klocek S et al. Exploring side-chain diversity by submonomer solid-phase aza-peptide synthesis. Org. Lett. 11(16), 3650-3653 (2009).
11. Gibson C, Goodman SL, Hahn D, Holzemann G, Kessler H. Novel solid-phase synthesis of azapeptides and azapeptoides via FMOC-strategy and its application in the synthesis of RGD-mimetics. J. Org. Chem. 64(20), 7388-7394 (1999).
12. Sulyok GAG, Gibson C, Goodman, SL, Hölzemann G, Wiesner M, Kessler H. Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective avb3 integrin antagonists. J. Med. Chem. 44(12), 1938-1950 (2001). (Pubitemid 32884518)
13. Malachowski WP, Tie C, Wang K, Broadrup RL. The synthesis of azapeptidomimetic b-lactam molecules as potential protease inhibitors. J. Org. Chem. 67(25), 8962-8969 (2002). (Pubitemid 35471122)
14. Boeglin D, Lubell WD. Aza-amino acid scanning of secondary structure suited for solid-phase peptide synthesis with fmoc chemistry and aza-amino acids with heteroatomic side chains. J. Comb. Chem. 7(6), 864-878 (2005) (Pubitemid 41705917)
15. Boeglin D, Xiang Z, Sorenson NB, Wood MS, Haskell-Luevano C, Lubell WD. Aza-scanning of the Potent melanocortin receptor agonist Ac-His-d-Phe-Arg-Trp- NH2. Chem. Biol. Drug Des. 67(4), 275-283 (2006).
16. Freeman NS, Hurevich M, Gilon C. Synthesis of Ń-substituted Ddz-protected hydrazines and their application in solid phase synthesis of aza-peptides. Tetrahedron 65(8), 1737-1745 (2009).
17. Han H, Janda KD. Azatides: solution and liquid phase syntheses of a new peptidomimetic. J. Am. Chem. Soc. 118(11), 2539-2544 (1996). (Pubitemid 26130431)
18. Han H, Yoon J, Janda KD. Investigations of azapeptides as mimetics of Leu-enkephalin. Bioorg. Med. Chem. Lett. 8(1), 117-120 (1998). (Pubitemid 28021705)
19. Hansen TK. Synthesis of azapeptides from hindered amines leading to novel growth hormone secretagogues. Tetrahedron Lett. 40(51), 9119-9120 (1999).
20. Randolph JT, Zhang X, Huang PP et al. Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor. Bioorg. Med. Chem. Lett. 18(8), 2745-2750 (2008). (Pubitemid 351503863)
21. André F, Boussard G, Bayeul D, Didierjean C, Aubry A, Marraud M. Aza-peptides II. X-ray structures of aza-alanine and aza-asparagine-containing peptides. J. Pept. Res. 49(6), 556-562 (1997). (Pubitemid 27335000)
22. Zega A, Mlinsek G, Sepic P et al. Design and structure-activity relationship of thrombin inhibitors with an azaphenylalanine scaffold: potency and selectivity enhancements via P2 optimization. Bioorg. Med. Chem. 9(10), 2745-2756 (2001). (Pubitemid 32824175)
23. Bailey MD, Halmos T, Goudreau N, Lescop E, Llins-Brunet M. Novel azapeptide inhibitors of hepatitis C virus serine protease. J. Med. Chem. 47(15), 3788-3799 (2004). (Pubitemid 38900344)
24. Wieczerzak E, Drabik P, Łankiewicz L et al. Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J. Med. Chem. 45(19), 4202-4211(2002). (Pubitemid 35033485)
25. Mhidia R, Melnyk O. Selective cleavage of an azaGly peptide bond by copper(II).Long-range effect of histidine residue. J. Pept. Sci. 16(3), 141-147(2010).
26. Boeglin D, Hamdan FF, Melendez RE et al. Calcitonin gene-related peptide analogues with aza and indolizidinone amino acid residues reveal conformational requirements for antagonist activity at the human calcitonin gene-related peptide 1 receptor. J. Med. Chem. 50(6), 1401-1408(2007). (Pubitemid 46496336)
27. Proulx C, Lubell WD. Solid-phase synthesis of aza-proline analogs of GHRP-6. Peptides: Breaking Away. Proceedings of the 21st American Peptide Symposium. Lebl M (Ed.).Prompt Scientific Publishing, San Diego, CA, USA 56-57 (2009).
28. Semple JE, Rowley DC, Brunck TK, Ripka WC. Synthesis and biological activity of P2-P4 azapeptidomimetic P1-argininal and P1-ketoargininamide derivatives: a novel class of serine protease inhibitors. Bioorg. Med. Chem. Lett. 7(3), 315-320(1997). (Pubitemid 27062941)
29. Zouikri M, Vicherat A, Aubry A, Marraud M, Boussard G. Azaproline as a b-turn-inducer residue opposed to proline. J. Pept. Res. 52(1), 19-26(1998). (Pubitemid 28347603)
30. de los Santos JM, Lopez Y, Aparicio D, Palacios F. A convenient synthesis of substituted pyrazolidines and azaproline derivatives through highly regio- and diastereoselective reduction of 2-pyrazolines. J. Org. Chem. 73(2), 550-557 (2007). (Pubitemid 351437414)
31. Mish MR, Guerra FM, Carreira EM. Asymmetric dipolar cycloadditions of Me3SiCHN2. Synthesis of a novel class of amino acids: azaprolines. J. Am. Chem. Soc. 119(35), 8379-8380 (1997). (Pubitemid 27390645)
32. O'Donnell MJ, Zhou C, Scott WL. Solid-phase unnatural peptide synthesis (UPS).J. Am. Chem. Soc. 118(25), 6070-6071 (1996). (Pubitemid 26236829)
33. Bourguet CB, Sabatino D, Lubell WD. Benzophenone semicarbazone protection strategy for synthesis of aza-glycine containing aza-peptides. Pept. Sci. 90(6), 824-831(2008).
34. Proulx C, Lubell WD. Aza-1,2,3-triazole-3- alanine synthesis via copper-catalyzed 1,3-dipolar cycloaddition on aza-progargylglycine. J. Org. Chem. 75(15), 5385-5387(2010).
35. Proulx C, Lubell WD. Copper-catalyzed N-arylation of semicarbazones for the synthesis of aza-arylglycine-containing aza-peptides. Org. Lett. 12(13), 2916-2919 (2010).
36. Gante J, Neunhoeffer H, Schmidt A. Peptide analog systems. 9. Synthesis of 1,2,4-triazines. 16. bridged azapeptides, a class of novel 1,4,5,6-tetrahydro-1,2,4- triazin-3(2H)ones. J. Org. Chem. 59(21), 6487-6489 (1994). (Pubitemid 24351162)
37. Dyker H, Scherkenbeck J, Gondol D, Goehrt A, Harder A. Azadepsipeptides: synthesis and evaluation of a novel class of peptidomimetics. J. Org. Chem. 66(11), 3760-3766 (2001). (Pubitemid 32867615)
38. Thormann M, Hofmann HJ. Conformational properties of azapeptides. J. Mol. Struct. (Theochem).469(1-3), 63-76 (1999).
39. Jeffrey GA. The structures of some small molecules. Ab initio molecular orbital calculations versus low temperature neutron diffraction crystal structure analyses. J. Mol. Struct. (Theochem).108(1-2), 1-15 (1984).
40. Ramondo F, Bencivenni L. Molecular conformation of isolated and hydrogen bonded N,Ń-diformohydrazide: an ab initio study. J. Chem. Soc. Perkin Trans. 2. 9, 1797-1804 (1995).
41. Reynolds CH, Hormann E. Theoretical study of the structure and rotational flexibility of diacylhydrazines: implications for the structure of nonsteroidal ecdysone agonist and azapeptides. J. Am. Chem. Soc. 118(39), 9395-9401 (1996). (Pubitemid 26355135)
42. Chakravorty S, Reynolds CH. Improved AMBER torsional parameters for the N-N rotational barrier in diacylhydrazines. J. Mol. Graphics Mod. 17, 315-324 (1999). (Pubitemid 32250318)
43. Bryantsev VS, Firman TK, Hay BP. Conformational analysis and rotational barriers of alkyl- and phenyl-substituted urea derivatives. J. Phys. Chem. A. 109(5), 832-842 (2005). (Pubitemid 40213224)
44. Semetey V, Hemmerlin C, Didierjean C et al. Unexpected stability of the urea cis-trans isomer in urea-containing model pseudopeptides. Org. Lett. 3(24), 3843-3846 (2001).
45. Bishop GJ, Price BJ, Sutherland IO. Torsional barriers in N,Ń-diacylhydrazines. J. Chem. Soc. Chem. Commun. 14, 672-674 (1967).
46. Fletcher JR, Sutherland IO. Conformational changes in tetra-alkylhydrazines. J. Chem. Soc. Chem. Commun. 13, 706-708 (1969).
47. Lee HJ, Lee MH, Choi YS, Park HM, Lee KB. NBO approach to evaluate origin of rotational barrier of diformylhydrazine. J. Mol. Struct. (Theochem).631(1-3), 101-110 (2003).
48. Lee HJ, Lee KB, Ahn IA, Ro S, Choi KH, Choi YS. Role of azaamino acid residue in b-turn formation and stability in designed peptide. J. Pept. Res. 56(1), 35-46 (2000). (Pubitemid 30435436)
49. Ro S, Yoon CJ. Conformational preference of acetyl-azaalanine-N-methyl amide. Z. Phys. Chem. 214(12), 1699-1706 (2000).
50. Lee HJ, Choi KH, Ahn IA et al. The b-turn preferential solution conformation of a tetrapeptide containing an azaamino acid residue. J. Mol. Struct. 569(1-3), 43-54 (2001).
51. Lee HJ, Song JW, Choi, YS, Park HM, Lee KB. A theoretical study of conformational properties of N-methyl azapeptide derivatives. J. Am. Chem. Soc. 124(40), 11881-11893 (2002).
52. Lee HJ, Jung HJ, Kim JH, Park HM, Lee KB. Conformational preference of azaglycine-containing dipeptides studied by PCM and IPCM methods. Chem. Phys. 294(2), 201-210 (2003).
53. Lee HJ, Park HM, Lee KB. The b-turn scaffold of tripeptide containing an azaphenylalanine residue. Biophys. Chem. 125(1), 117-126 (2007).
54. Richardson JS. The anatomy and taxonomy of protein structure. Adv. Protein Chem. 34, 167-339 (1981).
55. Hutchinson EG, Thornton JM. A revised set of potentials for b-turn formation in proteins. Protein Sci. 3, 2207-2216 (1994).
56. Zhang WJ, Berglund A, Kao JL, Couty JP, Gershengorn MC, Marshall GR. Impact of azaproline on amide cis-trans isomerism: conformational analyses and NMR studies of model peptides including TRH analogues. J. Am. Chem. Soc. 125(5), 1221-1235 (2003). (Pubitemid 36159833)
57. Che Y, Marshall GR. Impact of azaproline on peptide conformation. J. Org. Chem. 69(26), 9030-9042 (2004). (Pubitemid 40004022)
58. André F, Vicherat A, Boussard G, Aubry A, Marraud M. Aza-peptides. III. Experimental structural analysis of aza-alanine and aza-asparagine- containing peptides. J. Pept. Res. 50(5), 372-381 (1997). (Pubitemid 27469143)
59. Lecoq A, Boussard G, Marraud M, Aubry A. Crystal state conformation of three azapeptides containing the azaproline residue, a b-turn regulator. Biopolymers 33(7), 1051-1059 (1993). (Pubitemid 23184440)
60. Marraud M, Aubry A. Crystal structures of peptides and modified peptides. Pept. Sci. 40(1), 45-83 (1996).
61. Benatalah Z, Aubry A, Boussard G, Marraud M. Evidence for a b-turn in an azadipeptide sequence. Synthesis and crystal structure of ButCO-Pro-AzaAla- NHPri. Int. J. Pept. Protein. Res. 38(6), 603-605 (1991).
62. Gante J, Krug M, Lauterbach G, Weitzel R, Hiller W. Synthesis and properties of the first all-aza analogue of a biologically active peptide. J. Pept. Sci. 1(3), 201-206 (1995).
63. Hemmerlin C, Cung MT, Boussard G. Synthesis and conformational preferences in solution and crystalline states of an aza-tripeptide. Tetrahedron Lett. 42(30), 5009-5012 (2001). (Pubitemid 32607382)
64. André F, Marraud M, Boussard G. Synthesis and structure of azasx-pro-containing aza-peptides. Tetrahedron Lett. 37(2), 183-186 (1996). (Pubitemid 126335296)
65. Bac A, Rivoal K, Cung M et al. Conformational disturbance induced by AzPro/Pro substitution in peptides. Lett. Pept. Sci. 4(4), 251-258 (1997). (Pubitemid 127505456)
66. Kelly SM, Jess TC, Price NC. How to study proteins by circular dichroism. Biochim. Biophys. Acta Proteins Proteomics 1751(2), 119-139 (2005). (Pubitemid 41112231)
67. Bush CA, Sarkar SK, Kopple KD. Circular dichroism of b turns in peptides and proteins. Biochemistry 17(23), 4951-4954 (1978).
68. Gante J. Azapeptides. Synthesis 6, 405-413 (1989).
69. Hess H-J, Moreland WT, Laubach GD. N-[2-isopropyl-3-(l-aspartyl-l- arginyl)- carbazoyl]-l- tyrosyl-l-valyl-l-histidyl-l-prolyl-l-phenylalanine, an isostere of bovine angiotensin II. J. Am. Chem. Soc. 85(24), 4040-4041 (1963).
70. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. The Lancet 360(9327), 103-108(2002). (Pubitemid 34786197)
71. Zega A, Urleb U. Azapeptides. Acta Chim. Slov. 49, 640-662 (2002).
72. Zega A. Azapeptides as pharmacological agents. Curr. Med. Chem. 12, 589-597 (2005). (Pubitemid 40331053)
73. Hart M, Beeson C. Utility of azapeptides as major histocompatibility complex class II protein ligands for T-cell activation. J. Med. Chem. 44(22), 3700-3709 (2001). (Pubitemid 33026678)
74. Andurkar SV, Béguin C, Stables JP, Kohn H. Synthesis and structural studies of aza analogues of functionalized amino acids: new anticonvulsant agents. J. Med. Chem. 44(9), 1475-1478 (2001). (Pubitemid 32852125)
75. Wipf P, Li W, Adeyeye CM, Rusnak JM, Lazo JS. Synthesis of chemoreversible prodrugs of ara-C with variable time-release profiles. Biological evaluation of their apoptotic activity. Bioorg. Med. Chem. 4(10), 1585-1596 (1996). (Pubitemid 26361863)
76. Weber D, Berger C, Eickelmann P, Antel J, Kessler H. Design of selective peptidomimetic agonists for the human orphan receptor BRS-3. J. Med. Chem. 46(10), 1918-1930 (2003). (Pubitemid 36532234)
77. Perona JJ, Craik CS. Structural basis for substrate specificity in the serine proteases. Protein Sci. 4(3), 337-360 (1995).
78. Otto HH, Schirmeister T. Cysteine proteases and their inhibitors. Chem. Rev. 97(1), 133-172 (1997).
79. Kwong AD, Kim JL, Rao G, Lipovsek D, Raybuck SA. Hepatitis C virus NS3/4A protease. Antiviral Res. 40(1-2), 1-18 (1998). (Pubitemid 28535168)
80. Lundblad RL, Bradshaw RA, Gabriel D, Ortel TL, Lawson J, Mann KG. A review of the therapeutic uses of thrombin. Thromb. Haemost. 91(5), 851-860 (2004). (Pubitemid 38647487)
81. Sajid M, McKerrow JH. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasit. 120(1), 1-21 (2002). (Pubitemid 34159288)
82. Barrett A, Rawlings ND. Evolutionary lines of peptidases. Biol. Chem. 382(5), 727-733 (2001).
83. Joyce JA, Baruch A, Chehade J et al. Cathespin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5(5), 443-453 (2004). (Pubitemid 38610246)
84. Iwata Y, Mort JS, Tateishi H, Lee ER. Macrophage cathespin L, a factor in the erosion of subchondral bone in rheumatoid arthritis. Arthritis Rheum. 40(3), 499-509 (1997). (Pubitemid 27123666)
85. Lacaille F, Kaleta J, Bromme D. Human and parasitic papain-like cysteine proteases: their role in the physiology and pathology and recent developments in inhibitor design. Chem. Rev. 102(12), 4459-4488 (2002).
86. Denault JB, Salvesen GS. Caspases: keys in the ignition of cell death. Chem. Rev. 102(12), 4489-4500 (2002).
87. Bilsland J, Harper S. Caspases and neuroprotection. Curr. Opin. Investig. Drugs 3(12), 1745-1752 (2002). (Pubitemid 36266721)
88. Smalley JW, Birss AJ, Kay HM, McKee AS, Marsh PD. The distribution of trypsin-like enzyme activity in cultures of a virulent and an avirulent strain of Bacteroides gingivalis W50. Oral Microbiol. Immunol. 4(3), 178-181 (1989).
89. Liu C, Sun CZ, Huang HN, Janda K, Edgington T. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 63(11), 2957-2964 (2003). (Pubitemid 36667169)
90. Mitchell WM, Harrington WF. Clostripain. Methods Enzymol. 19, 635-642 (1970).
91. Dutta AS, Giles M. Polypeptides. Part XIV. A comparative study of the stability towards enzymes of model tripeptides containing a-aza-amino acids, l-amino acids, and d-amino acids. J. Chem. Soc., Perkin Trans. 1 244-248 (1976).
92. Dutta, AS, Giles M, Williams J. Inhibitors of porcine pancreatic elastase. peptides incorporating a-aza-amino acid residues in the P1 position. J. Chem. Soc. Perkin Trans. 1 1655-1663 (1986).
93. Zhang R, Durkin JP, Windsor WT. Azapeptides as inhibitors of the hepatitis C virus NS3 protease. Bioorg. Med. Chem. Lett. 12(7), 1005-1008 (2002). (Pubitemid 34242789)
94. Powers JC, Boone R, Carroll DL et al. Reaction of azapeptides with human leukocyte elastase and porcine pancreatic elastase J. Biol. Chem. 259(7), 4288-4294 (1984). (Pubitemid 14127789)
95. Magrath J, Abeles RH. Cysteine protease inhibition by azapeptide esters J. Med. Chem. 35 (23), 4279-4283 (1992).
96. Xing R, Hanzlik RP. Azapeptides as inhibitors and active site titrants for cysteine proteinases. J. Med. Chem. 41(8), 1344-1351(1998). (Pubitemid 28208187)
97. Asgian JL, James KE, Li ZZ et al. Aza-peptide epoxides: a new class of inhibitors selective for clan CD cysteine proteases J. Med. Chem. 45(23), 4958-4960 (2002). (Pubitemid 35278691)
98. Frizler M, Stirnberg M, Sisay MT, Gütschow M. Development of nitrile-based peptidic inhibitors of cystein cathepsins. Curr. Top. Med. Chem. 10, 294-322 (2010).
99. Löser R, Frizler M, Schilling K, Gütschow M. Azadipeptide nitriles : highly potent and proteolytically stable inhibitors of papain-like cysteine proteases. Angew. Chem. Int. Ed. 47, 4331-4334 (2008).
100. Frizler M, Lohr F, Furtmann N, Kläs J, Gütschow M. Structural optimization of azadipeptide nitriles strongly increases association rates and allows the development of selective cathepsin inhibitors. J. Med. Chem. 54(1), 396-400 (2011).
101. James KE, Asgian JL, Li ZZ et al. Design, synthesis, and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases-1, -3, -6, and -8 J. Med. Chem. 47(6), 1553-1574 (2004). (Pubitemid 38327479)
102. Ovat A, Muindi F, Fagan C et al. Aza-peptidyl Michael acceptors and epoxide inhibitors-potent and selective inhibitors of Schistosoma mansoni and Ixodes ricinus legumains (asparaginyl endopeptidases) J. Med. Chem. 52(22), 7192-7210 (2009).
103. Ekici OD, Li ZZ, Campbell AJ et al. Design, synthesis and evaluation of aza-peptide Michael acceptors as selective and potent inhibitors of caspases-2, -3, -6, -7, -8, -9 and -10. J. Med. Chem. 49(19), 5728-5749 (2004).
104. Sexton KB, Kato D, Berger AB, Fonovic M, Verhelst SHL, Bogyo M. Specificity of aza-peptide electrophile activity-based probes of caspases. Cell Death Diff. 14(4), 727-732 (2007). (Pubitemid 46444510)
105. Ekici OD, Gotz MG, James KE et al. Aza-peptide Michael acceptors: a new class of inhibitors specific for caspases and other clan CD cysteine proteseas. J. Med. Chem. 47(8), 1889-1892 (2004). (Pubitemid 38453908)
106. Gotz MG, James KE, Hansell E et al. Aza-peptidyl Michael acceptors. a new class of potent and selective inhibitors of asparaginyl endopeptidases (legumains) from evolutionary diverse pathogens. J. Med. Chem. 51(9), 2816-2832 (2008). (Pubitemid 351620803)
107. Ganesan R, Jelakovic S, Campbell AJ et al. Exploring the S4 and S1 prime subsite specificities in caspase-3 with aza-peptide epoxide inhibitors. Biochemistry 45(30), 9059-9067 (2006). (Pubitemid 44156368)
108. Kato D, Verhelst SHL, Sexton KB, Bogyo M. A general solid-phase method for the preparation of diverse aza-peptide probes against cysteine proteases. Org. Lett. 7(25), 5649-5652 (2005). (Pubitemid 43010820)
109. Lee J, Bogyo M. Development of near-infrared fluorophore (NIRF)-labeled activity-based probes for in vivo imaging of legumain. Chem. Biol. 5(2), 233-243 (2010).